__timestamp | Amneal Pharmaceuticals, Inc. | Insmed Incorporated |
---|---|---|
Wednesday, January 1, 2014 | 106735000 | 56292000 |
Thursday, January 1, 2015 | 136870000 | 74277000 |
Friday, January 1, 2016 | 204747000 | 122721000 |
Sunday, January 1, 2017 | 191938000 | 109749000 |
Monday, January 1, 2018 | 210451000 | 145283000 |
Tuesday, January 1, 2019 | 202287000 | 131711000 |
Wednesday, January 1, 2020 | 190585000 | 181157000 |
Friday, January 1, 2021 | 209563000 | 272744000 |
Saturday, January 1, 2022 | 200046000 | 397518000 |
Sunday, January 1, 2023 | 167778000 | 571011000 |
Data in motion
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Insmed Incorporated and Amneal Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Insmed's R&D expenses surged by over 900%, reflecting its commitment to pioneering treatments. In contrast, Amneal's R&D spending remained relatively stable, with a modest increase of around 57%. This divergence highlights Insmed's aggressive strategy to expand its therapeutic portfolio, while Amneal focuses on optimizing existing products.
The year 2023 marked a significant milestone, with Insmed's R&D expenses peaking at nearly 3.4 times that of Amneal's. This trend underscores the dynamic nature of the industry, where strategic investments in R&D can redefine a company's competitive edge.
Analyzing R&D Budgets: Johnson & Johnson vs Insmed Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Merck & Co., Inc. and Insmed Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Sanofi and Insmed Incorporated
Gilead Sciences, Inc. vs Insmed Incorporated: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Viatris Inc. vs Insmed Incorporated
Analyzing R&D Budgets: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Comparing Innovation Spending: Insmed Incorporated and Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Amneal Pharmaceuticals, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Comparing Innovation Spending: Amneal Pharmaceuticals, Inc. and Xencor, Inc.